Formosa Pharmaceuticals Announces Licensing Agreement With Cristália for APP13007
Exhibitor: FORMOSA PHARMACEUTICALS , INC
Date: 2024-03-28
Booth No.: N/A
TAIPEI – January 26, 2024 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has entered into a licensing agreement with CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (“Cristália”), for exclusive Brazilian rights to the commercialization of APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for the treatment of inflammation and pain following ocular surgery. APP13007 is currently under review by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) date of March 4, 2024. The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.
APP13007’s active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma’s proprietary APNT™ nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain, which in Phase 3 trials proved statistically and clinically superior to its matching placebo (p<0.001). If approved, APP13007 will join in a potential and growing market in Brazil for topical ophthalmic steroids.
“We are honored to establish this partnership with Cristália, with its storied history in Brazilian pharmaceuticals and expertise in eye health. Given their dedication to bringing innovation to the market, we are confident APP13007 will reach its potential in providing ophthalmologists and patients a powerful option in recovering from ocular surgery,” said Erick Co, President and CEO of Formosa Pharmaceuticals.
Ricardo S. Pacheco, Chairman of Cristália stated: “We are pleased to have entered into this agreement with our development partner, Formosa Pharmaceuticals. If approved, APP13007 will be an attractive new treatment option to ophthalmic surgeons and their patients in Latin America with a convenient posology. Once is approved, Cristália will go full steam ahead with commercialization.”
More Exhibitor's Press Release
- EHPC-Semiconductors, pharmaceuticals, biotechnology, clean room materials EASTERN HIGH PURITY CONNECTION CO., LTD / 2024-04-29
- INORA Brand Strategy to Drive Revenue Growth INORA PHARMACEUTICAL MACHINERY CO., LTD. / 2024-04-26
- Medical Micro Molding Solutions ANN TONG INDUSTRIAL CO.,LTD / 2024-04-18
- Macrogen becomes the first company in Asia to adopt the next generation of genome sequencing technol MACROGEN, INC. / 2024-04-17
- Macrogen becomes the first company to bring NovaSeq X Plus to Korea, marking its first introduction MACROGEN, INC. / 2024-04-17
- Wendy International LTD. Introduction WENDY INTERNATIONAL LTD / 2024-04-17
- ABLE Biott Disposable Bioreactor MITEKLAB CO., LTD. / 2024-04-10
- Femtika SLE technology permits the microfabrication of complex-shaped microfluidic channels MICROSYS ENGINEERING CO., LTD / 2024-04-03
- Microqubic 2D/3D Microscopes and Modular Imaging Systems MICROSYS ENGINEERING CO., LTD / 2024-04-03
- Yenchen Machinery Started Being Enwave Optronics Exclusive Agent PAT(Process Analytical Technology) YENCHEN MACHINERY CO., LTD. / 2024-04-02
- Yenchen acts as agent of NFA Automatic Tablet & Capsule Inspection Machine YENCHEN MACHINERY CO., LTD. / 2024-04-02
- Amaran Biotech Introduces the First Fully-Automated Robotic Aseptic Filling Line in Taiwan AMARAN BIOTECHNOLOGY, INC. / 2024-04-01
- Videojet Ink Jet Print A&D Metal Detector A&D CHECK WEIGHER X-Ray TAIDEVELOP ID TECH CO., LTD. / 2024-03-30
- Videojet Ink Jet Print A&D Metal Detector A&D CHECK WEIGHER TAIDEVELOP ID TECH CO., LTD. / 2024-03-30
- AND Metal Detector check weigher X-RAY Videojet Ink Jet Print TAIDEVELOP ID TECH CO., LTD. / 2024-03-30
- Formosa Pharmaceuticals Announces Licensing Agreement With Eyenovia for APP13007 Commercialization FORMOSA PHARMACEUTICALS , INC / 2024-03-28
- Formosa Pharmaceuticals Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05% FORMOSA PHARMACEUTICALS , INC / 2024-03-28
- Old-established brand of Vacuum Emulsifying Mixer in Taiwan - Minoga Industrial Co., Ltd. MINOGA INDUSTRIAL CO., LTD. / 2024-03-27
- National Defense Medical Center 2024 Bio Asia-Taiwan Exhibition Projects NATIONAL DEFENSE MEDICAL CENTER / 2024-03-27
- Introduction of National Defense Medical Center NATIONAL DEFENSE MEDICAL CENTER / 2024-03-27